Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by Bigkahuna57 on Apr 05, 2022 8:56pm

Today

Thank you to everyone that add clarity to the confusion.  I truly appreciate the time and effort. 

One thing that I wish we could see is where the patients are being tested, and which sites are showing the best results.  I'm sure Dr. Mad. is carefully looking into the protocols.  She is 1 of 2 great highlights of 2021. 

With the "optimized treatment" data and performance time lines performing well above Keytruda data (not to mention the possible adverse side effects), the SP may not rise as fast as it retreated today, but it will get back to new highs somtime in June.  If not before then, should we see BTD.  IMO.

With the number of treatments, safety profile, and current/pending results - I'm very surprised that the sp is where it is.  I'm not the fist to say this today, but big pharma is taking notice.  The artificially low sp is speaking.  

Another 90 days of hope for the next patients and those in program.

Good luck to all.
Regards,BK
Comment by chry200030 on Apr 05, 2022 9:20pm
Today was an over reaction. The share price will rebound nicely in the days ahead.  Another 90 days for the next report is nothing.  The reward will be worth the wait.
Comment by CancerSlayer on Apr 05, 2022 10:50pm
I must be the only one working? : ).  Just got off work & haven't gotten to all of the posts, but a quick review of the data looks very reassuring.  Firstly, all data after 90 days is not very meaningful to me.  There are just too many pending patients to make any valid conclusions.  The most meaningful data to focus on is the 90 day CR & the potential CR in " ...more  
Comment by Rumpl3StiltSkin on Apr 05, 2022 11:21pm
Thanks Doc for a moment of sanity among a sea of woe. I agree. When I first saw these numbers today in the update, I thought yeah things look on track. It even looked like the data presentation was an improvement over the ones in recent memory. Much less confusing, to me, They put it in databoxes and even put some data in bold. So when I saw SP was down premarket I thought hmm, sell the news? It ...more  
Comment by stocksnbonds458 on Apr 05, 2022 11:25pm
Thankyou CancerSlayer, enriquesauve and others for your good work here. You guys are the only ones that can make sense of these muddled news releases and present them to us in language we can understand. Your time spent deciphering TLT encryption is much appreciated! As for TLT, shame on you!!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250